Report from Annual General Meeting in SyntheticMR AB

Report this content

The Annual General Meeting (AGM) of SyntheticMR AB (publ) was held on April 29, 2019, whereby the meeting resolved in accordance with the Board's proposed resolutions. The full resolutions are stated in the notice of the meeting.

During his presentation at the Annual General Meeting, CEO Stefan Tell talked about, among other things, the development during 2018.

“2018 was a year of continued sales growth and SyntheticMR has a good financial position. This creates both flexibility for future investments and legitimacy for the company. The sale of MAGiC continued with good growth and GE Healthcare launched MAGiC in the reading room. Furthermore, MAGiC was approved for sale in the Chinese market through the clearance of the China Food and Drug Adminitration (CFDA). Siemens launched SyMRI as an application in the launch of syngo.via Open apps. In 2018 we also received regulatory approval from the FDA for SyMRI together with the MR system from GE Healthcare and Philips,” says Stefan Tell

The following resolutions were made at the AGM:

The AGM resolved to approve the Board's dividend proposal that the profits available to the Meeting should be allocated so that the shareholders will be paid SEK 1.50 per share. The remaining capitalized funds of SEK 33,883,349 including the share premium reserve and retained earnings, are carried forward.

The AGM resolved to grant the Board of directors and CEO discharge.

The AGM decided that the Board should consist of 4 ordinary members and no deputies. The re-election of the Board members, Jan Bertus Marten Warntjes, Johan Sedihn, Yvonne Mårtensson and Staffan Persson. Yvonne Mårtensson is elected as the new Chairman of the Board.

For further information, please contact Fredrik Jeppsson, acting CEO, +46 72 303 13 39

SyntheticMR AB develops and markets innovative software solutions for Magnetic Resonance Imaging (MRI). SyntheticMR AB has developed SyMRI® delivering multiple, adjustable contrast images and quantitative data from a single 5-6-minute scan – generating increased patient throughput and objective decision support for clinicians. SyMRI is CE-marked and FDA 510(k) cleared. SyMRI is a registered trademark in Europe and in the USA. SyntheticMR is listed on the Spotlight Stock exchange in Stockholm, Sweden. For additional information, please visit


Documents & Links